Blood Protein NfL Predicts Cognitive Decline and Death Risk in Centenarians
A Japanese study of 495 centenarians finds elevated NfL blood levels strongly linked to worse cognition and 36% higher mortality risk.
Summary
A study of nearly 500 Japanese centenarians found that neurofilament light chain (NfL), a protein released into the blood when nerve cells are damaged, is a powerful predictor of both cognitive decline and death risk in people over 100. Those with higher NfL levels scored worse on memory and thinking tests and faced a 36% higher risk of dying during the follow-up period. Importantly, NfL outperformed classic Alzheimer's biomarkers like amyloid and tau in predicting mortality, suggesting it reflects broader nervous system and body-wide health rather than just Alzheimer's disease pathology. These findings, replicated across Danish and Japanese cohorts, position NfL as a promising universal aging biomarker.
Detailed Summary
Researchers studying centenarians have identified a single blood protein that may reveal how well the brain and body are holding up at the extreme limits of human lifespan. Neurofilament light chain, or NfL, is a structural component of nerve cells that leaks into the bloodstream when neurons are damaged. A new Japanese cohort study published in JAMA Network Open found that elevated plasma NfL levels in people over 100 years old were strongly associated with poorer cognitive performance and significantly higher risk of death.
The study followed 495 Japanese centenarians with a mean age of 104 years, recruited between 2000 and 2021 and tracked for up to 17 years. Participants with higher NfL levels scored meaningfully lower on the Mini-Mental Status Examination, a standard cognitive assessment. Crucially, elevated NfL was tied to a 36% increase in mortality risk, even after adjusting for confounding variables.
What makes NfL stand out is its apparent breadth as a biomarker. Unlike amyloid-beta 42/40 and phosphorylated tau 181, two well-known Alzheimer's disease markers that were linked to cognitive scores but not mortality after adjustment, NfL appeared to capture systemic interactions between the nervous system, immune function, and vascular health. Researchers suggest this makes it a more generalizable indicator of biological aging and neurodegeneration.
These findings replicate earlier results from Danish nonagenarian and centenarian cohorts, lending cross-population credibility. Researchers are now exploring NfL as a cross-species biomarker, potentially useful for evaluating aging interventions in animal models before human trials.
For health-conscious individuals, NfL is increasingly available through specialized blood panels and is already used clinically in neurological conditions. While not yet standard in preventive care, its predictive power across populations suggests it may become a key tool for tracking brain and systemic health as we age.
Key Findings
- Higher blood NfL levels in centenarians linked to 36% increased mortality risk after full statistical adjustment.
- Elevated NfL correlated with significantly lower cognitive scores on standard memory and thinking tests.
- NfL outperformed Alzheimer's biomarkers amyloid and tau in predicting mortality in people over 100.
- Findings replicated across Japanese and Danish centenarian cohorts, strengthening cross-population validity.
- NfL may reflect systemic aging across immune, vascular, and nervous systems, not just brain disease.
Methodology
This is a research summary based on a peer-reviewed cohort study published in JAMA Network Open, a credible open-access journal. The study followed 495 Japanese centenarians for up to 17 years with baseline blood sampling and cognitive testing. Evidence quality is strengthened by longitudinal design, statistical adjustment for confounders, and independent replication in a separate Danish cohort.
Study Limitations
The study population is exclusively Japanese centenarians, limiting direct generalizability to younger or ethnically diverse populations. The article is a news summary and does not provide full methodological detail; readers should consult the primary JAMA Network Open paper. Causality cannot be established from cohort data, and NfL is not yet validated as a routine preventive screening tool.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.